Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.31 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.31 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21584826 | 0.84 | NPC1 (0.40) | PDE10AKCNN3NPC1RAB9A | |
| SCHEMBL18780955 | 0.83 | TLR7 (0.41) | PDE10A | |
| SCHEMBL1018995 | 0.83 | NOS2 (0.41) | — | |
| SCHEMBL22176046 | 0.81 | KDM4E (0.42) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL311906 | 0.80 | TP53 (0.47) | PDE10ANPC1RAB9ACRHR1 | |
| SCHEMBL1934522 | 0.76 | PDE10A (0.48) | PDE10ANPC1RAB9A | |
| SCHEMBL23649060 | 0.73 | PDE10A (0.50) | PDE10ANPC1RAB9A | |
| SCHEMBL26127921 | 0.73 | PDE10A (0.46) | PDE10AKCNN3NPC1RAB9A | |
| SCHEMBL5437664 | 0.72 | NOS3 (0.30) | — | |
| SCHEMBL1348663 | 0.72 | TP53 (0.45) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| CN-111620865-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3753943-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369676-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-26 | — | — | US | disclosed |
| CN-111620864-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111620865-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-110156772-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | ENPP2, ATXN10, PCSK9 | PDE10A 354/4885KCNN3 1456/4885KCNN1 1965/4885 |
| US-20200369676-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ENPP2, ATXN10, PCSK9 | PDE10A 354/4885KCNN3 1456/4885KCNN1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.